ES2326115T3 - Derivados de la quinoleina, procedimiento de sintesis, y medicamentos que contienen estos derivados. - Google Patents
Derivados de la quinoleina, procedimiento de sintesis, y medicamentos que contienen estos derivados. Download PDFInfo
- Publication number
- ES2326115T3 ES2326115T3 ES02795314T ES02795314T ES2326115T3 ES 2326115 T3 ES2326115 T3 ES 2326115T3 ES 02795314 T ES02795314 T ES 02795314T ES 02795314 T ES02795314 T ES 02795314T ES 2326115 T3 ES2326115 T3 ES 2326115T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- derivatives
- defined above
- acid
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 17
- 230000015572 biosynthetic process Effects 0.000 title claims description 9
- 238000003786 synthesis reaction Methods 0.000 title claims description 9
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical class C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 title description 10
- 229940079593 drug Drugs 0.000 title description 7
- -1 -COOR Chemical group 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 11
- 238000007127 saponification reaction Methods 0.000 claims description 9
- GFYMLRYNGZEAFF-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylcarbamoyl]-8-hydroxyquinoline-7-carboxylic acid Chemical compound N=1C2=C(O)C(C(=O)O)=CC=C2C=CC=1C(=O)NCC1=CC=C(O)C(O)=C1 GFYMLRYNGZEAFF-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 125000006850 spacer group Chemical group 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 230000020477 pH reduction Effects 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- XCUIQBHAIMNBMZ-UHFFFAOYSA-N 2-[(2,4-dihydroxyphenyl)methylcarbamoyl]-8-hydroxyquinoline-7-carboxylic acid Chemical compound N=1C2=C(O)C(C(=O)O)=CC=C2C=CC=1C(=O)NCC1=CC=C(O)C=C1O XCUIQBHAIMNBMZ-UHFFFAOYSA-N 0.000 claims description 4
- IITSQEXMDOMDMJ-UHFFFAOYSA-N 8-hydroxy-2-[(2,3,4-trihydroxyphenyl)methylcarbamoyl]quinoline-7-carboxylic acid Chemical compound N=1C2=C(O)C(C(=O)O)=CC=C2C=CC=1C(=O)NCC1=CC=C(O)C(O)=C1O IITSQEXMDOMDMJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 230000036436 anti-hiv Effects 0.000 claims description 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229940124524 integrase inhibitor Drugs 0.000 claims description 2
- 239000002850 integrase inhibitor Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003248 quinolines Chemical class 0.000 claims description 2
- GKHAQRADKBTIKK-UHFFFAOYSA-N 2-carbamoyl-8-hydroxyquinoline-7-carboxylic acid Chemical class C1=CC(C(O)=O)=C(O)C2=NC(C(=O)N)=CC=C21 GKHAQRADKBTIKK-UHFFFAOYSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 abstract description 3
- 102000012330 Integrases Human genes 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 241001430294 unidentified retrovirus Species 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000004452 microanalysis Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 108020005202 Viral DNA Proteins 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- RNQDBXNSZOJBET-UHFFFAOYSA-N 7-butoxycarbonyl-8-(2,2-dimethylpropanoyloxy)quinoline-2-carboxylic acid Chemical compound C1=CC(C(O)=O)=NC2=C(OC(=O)C(C)(C)C)C(C(=O)OCCCC)=CC=C21 RNQDBXNSZOJBET-UHFFFAOYSA-N 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IMTUBZOIPOXUTD-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) quinoline-2-carboxylate Chemical compound C=1C=C2C=CC=CC2=NC=1C(=O)ON1C(=O)CCC1=O IMTUBZOIPOXUTD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- SHOHIXCIFBPUAP-UHFFFAOYSA-N 8-hydroxy-2-methylquinoline-7-carboxylic acid Chemical compound C1=CC(C(O)=O)=C(O)C2=NC(C)=CC=C21 SHOHIXCIFBPUAP-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- LKOJGUIQTPXLPY-UHFFFAOYSA-N 8-(2,2-dimethylpropanoyloxy)-2-formylquinoline-7-carboxylic acid Chemical compound C1=C(C=O)N=C2C(OC(=O)C(C)(C)C)=C(C(O)=O)C=CC2=C1 LKOJGUIQTPXLPY-UHFFFAOYSA-N 0.000 description 1
- FTOLVLYBMNNTMN-UHFFFAOYSA-N 8-(2,2-dimethylpropanoyloxy)-2-methylquinoline-7-carboxylic acid Chemical compound C1=CC(C(O)=O)=C(OC(=O)C(C)(C)C)C2=NC(C)=CC=C21 FTOLVLYBMNNTMN-UHFFFAOYSA-N 0.000 description 1
- JYIAZVFJRYLCBH-UHFFFAOYSA-N 8-hydroxyquinoline-7-carboxylic acid Chemical compound C1=CC=NC2=C(O)C(C(=O)O)=CC=C21 JYIAZVFJRYLCBH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035892 strand transfer Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0113209A FR2830863B1 (fr) | 2001-10-12 | 2001-10-12 | Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives |
| FR0113209 | 2001-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2326115T3 true ES2326115T3 (es) | 2009-10-01 |
Family
ID=8868255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02795314T Expired - Lifetime ES2326115T3 (es) | 2001-10-12 | 2002-10-14 | Derivados de la quinoleina, procedimiento de sintesis, y medicamentos que contienen estos derivados. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7064133B2 (enExample) |
| EP (1) | EP1461319B1 (enExample) |
| JP (1) | JP2005508350A (enExample) |
| AT (1) | ATE430134T1 (enExample) |
| DE (1) | DE60232186D1 (enExample) |
| DK (1) | DK1461319T3 (enExample) |
| ES (1) | ES2326115T3 (enExample) |
| FR (1) | FR2830863B1 (enExample) |
| IL (2) | IL161320A0 (enExample) |
| WO (1) | WO2003031413A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2830863B1 (fr) * | 2001-10-12 | 2004-01-30 | Bioalliance Pharma | Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives |
| FR2839646B1 (fr) | 2002-05-17 | 2008-04-11 | Bioalliance Pharma | Utilisation de derives de quinoleine a effet anti-integrase et ses applications |
| US7132432B2 (en) * | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| WO2005028478A1 (en) | 2003-09-19 | 2005-03-31 | Gilead Sciences, Inc. | Aza-quinolinol phosphonate integrase inhibitor compounds |
| WO2006129134A1 (en) * | 2005-06-01 | 2006-12-07 | Bioalliance Pharma | Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2761687B1 (fr) * | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| FR2830863B1 (fr) * | 2001-10-12 | 2004-01-30 | Bioalliance Pharma | Derives de quinoleine, procede de synthese, et medicaments renfermant ces derives |
-
2001
- 2001-10-12 FR FR0113209A patent/FR2830863B1/fr not_active Expired - Fee Related
-
2002
- 2002-10-14 ES ES02795314T patent/ES2326115T3/es not_active Expired - Lifetime
- 2002-10-14 JP JP2003534397A patent/JP2005508350A/ja active Pending
- 2002-10-14 DK DK02795314T patent/DK1461319T3/da active
- 2002-10-14 AT AT02795314T patent/ATE430134T1/de not_active IP Right Cessation
- 2002-10-14 US US10/492,088 patent/US7064133B2/en not_active Expired - Fee Related
- 2002-10-14 DE DE60232186T patent/DE60232186D1/de not_active Expired - Lifetime
- 2002-10-14 WO PCT/FR2002/003512 patent/WO2003031413A1/fr not_active Ceased
- 2002-10-14 EP EP02795314A patent/EP1461319B1/fr not_active Expired - Lifetime
- 2002-10-14 IL IL16132002A patent/IL161320A0/xx unknown
-
2004
- 2004-04-07 IL IL161320A patent/IL161320A/en not_active IP Right Cessation
-
2006
- 2006-03-01 US US11/364,329 patent/US20060148849A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005508350A (ja) | 2005-03-31 |
| US20060148849A1 (en) | 2006-07-06 |
| EP1461319A1 (fr) | 2004-09-29 |
| FR2830863A1 (fr) | 2003-04-18 |
| ATE430134T1 (de) | 2009-05-15 |
| US7064133B2 (en) | 2006-06-20 |
| IL161320A (en) | 2009-09-01 |
| DK1461319T3 (da) | 2009-08-03 |
| FR2830863B1 (fr) | 2004-01-30 |
| WO2003031413A1 (fr) | 2003-04-17 |
| EP1461319B1 (fr) | 2009-04-29 |
| US20040259911A1 (en) | 2004-12-23 |
| IL161320A0 (en) | 2004-09-27 |
| DE60232186D1 (de) | 2009-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2332434T3 (es) | Derivados de quirolina como inhibidores de la integrasa del vih. | |
| Patil et al. | Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group | |
| Aggarwal et al. | Synthesis and biological evaluation of prodrugs of zidovudine | |
| US20150218120A1 (en) | Hiv integrase inhibitors | |
| US6541483B2 (en) | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | |
| NO973363D0 (no) | Neuraminsyrederivater, deres fremstilling og medisinske bruk | |
| Tillekeratne et al. | Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase | |
| ES2326115T3 (es) | Derivados de la quinoleina, procedimiento de sintesis, y medicamentos que contienen estos derivados. | |
| Sergheraert et al. | Synthesis and anti-HIV evaluation of D4T and D4T 5'-monophosphate prodrugs | |
| AU2007246814B2 (en) | Anti-viral pyrimidine nucleoside derivatives | |
| Li et al. | Hybrid molecules based on an emodin scaffold. Synthesis and activity against SARS-CoV-2 and Plasmodium | |
| JPH11507375A (ja) | 低分子によるｒｎａ／リガンド結合の阻害 | |
| EP2045246A1 (en) | Derivatives of benzo[d] isothiazoles as histone deacetylase inhibitors | |
| US20060094755A1 (en) | Novel quinoline-based metal chelators as antiviral agents | |
| CA2163174C (en) | Hindered aromatic ester compounds useful as anti-viral agents | |
| Al-Abed et al. | Inhibition of HIV-1 nuclear import via Schiff base formation with arylene bis (methylketone) compounds | |
| Maurin et al. | Design, synthesis, and anti-integrase activity of catechol–DKA hybrids | |
| US9108943B2 (en) | Photoreactive benzamide probes for histone deacetylase 2 | |
| RU2359954C2 (ru) | Производные бензотрополона, обладающие анти-вич активностью, фармацевтическая композиция, способ ингибирования вич-1 интегразы | |
| US20060063938A1 (en) | Compounds to treat hiv infection and aids | |
| CN119080839B (zh) | 一种抗病毒药物及其用途 | |
| Karaman et al. | Design, synthesis and in-vitro kinetic study of atovaquone prodrug for the treatment of malaria | |
| Kim et al. | A new synthetic analogue of thymidine, 7-(3-bromo-phenoxy)-thymidine, inhibits the proliferation of tumor cells | |
| Bader et al. | Discovery of a Novel Potent Inhibitor of HIV Infection | |
| US20060106070A1 (en) | Novel pyridine-based metal chelators as antiviral agents |